Cancer Research and Treatment

Nicolas Penel

1 Article

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Hyun Ae Jung, Antoine Adenis, Jeeyun Lee, Se Hoon Park, Chi Hoon Maeng, Silvia Park, Hee Kyung Ahn, Young Mog Shim, Nicolas Penel, Young-Hyuck Im; Cancer Res Treat. 2013;45(4):285-294. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.285

PURPOSE
The degree of benefit from palliative chemotherapy differs widely among patients with metastatic esophageal squamous cell carcinoma (MESCC). The purpose of this study was to develop and validate a prognostic nomogram to predict survival and aid physicians and patients in the decision-making process regarding treatment options.
MATERIALS AND METHODS
Clinicopathologic variables and treatment outcomes of 239 patients who were diagnosed with MESCC and received either fluorouracil/cisplatin (FP) or capecitabine/cisplatin (XP) as first-line chemotherapy were reviewed. A nomogram was developed as a prognostic scoring system incorporating significant clinical and laboratory variables based on a multivariate Cox proportional hazards regression model. An independent series of 61 MESCC patients treated with FP served as an independent data set for nomogram validation.
RESULTS
No difference in response rate was observed between the FP group (44.8%) and the XP group (54.2%). Similarly, no significant differences in median progression-free survival and median overall survival were observed between regimen groups. Multivariate analysis showed that poor performance status (Eastern Cooperative Oncology Group [ECOG] status> or =2), weight loss (10% of the weight loss for 3 months), low albumin level (< or =3.5 g/dL), and absence of previous esophagectomy at the time of chemotherapy were significantly associated with low OS in both groups (p<0.05). Based on these findings, patients were classified into favorable (score, 0 to 90), intermediate (91-134), and poor (>135) prognostic groups. The median survival for those with a favorable ECOG was 13.8 months (95% confidence interval [CI], 10.8 to 18.6 months), for intermediate 11.2 months (95% CI, 8.7 to 11.9 months), and for poor, 7.0 months (95% CI, 3.6 to 10.0 months). External validation of the nomogram in a different patient cohort yielded significantly similar findings.
CONCLUSION
The nomogram described here predicts survival in MESCC patients and could serve as a guide for the use of FP/XP chemotherapy in MESCC patients.

Citations

Citations to this article as recorded by

A population-based investigation: How to identify high-risk T1-2N0 esophageal cancer patients?
Peng Luo, Jie Wu, Xiankai Chen, Yafan Yang, Ruixiang Zhang, Xiuzhu Qi, Yin Li
Frontiers in Surgery.2023;[Epub] CrossRef
Low-Dose Versus High-Dose Radiation Therapy for the Palliation of Dysphagia From Esophageal Cancer: A Multicenter Retrospective Cohort Study
Bram D. Vermeulen, Paul M. Jeene, Jasmijn Sijben, Robin Krol, Heidi Rütten, Johannes A. Bogers, Pètra M. Braam, Peter D. Siersema
Practical Radiation Oncology.2020; 10(4): e255. CrossRef
Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles
Qingxia Fu, Jiancheng Wang, Hong Liu
Drug Delivery.2020; 27(1): 1535. CrossRef
A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study
Xin Tang, Xiaojuan Zhou, Yanying Li, Xue Tian, Yongsheng Wang, Meijuan Huang, Li Ren, Lin Zhou, Zhenyu Ding, Jiang Zhu, Yong Xu, Feng Peng, Jin Wang, You Lu, Youling Gong
Annals of Surgical Oncology.2019; 26(2): 321. CrossRef
SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
Héctor van den Boorn, Ameen Abu-Hanna, Emil ter Veer, Jessy van Kleef, Florian Lordick, Michael Stahl, Jaffer Ajani, Rosine Guimbaud, Se Park, Susan Dutton, Yung-Jue Bang, Narikazu Boku, Nadia Mohammad, Mirjam Sprangers, Rob Verhoeven, Aeilko Zwinderman,
Cancers.2019; 11(2): 187. CrossRef
Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery
Yoichi Hamai, Jun Hihara, Manabu Emi, Takaoki Furukawa, Yuji Murakami, Ikuno Nishibuchi, Yuta Ibuki, Ichiko Yamakita, Tomoaki Kurokawa, Yasushi Nagata, Morihito Okada
World Journal of Surgery.2018; 42(5): 1496. CrossRef
Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis
H. G. van den Boorn, E. G. Engelhardt, J. van Kleef, M. A. G. Sprangers, M. G. H. van Oijen, A. Abu-Hanna, A. H. Zwinderman, V. M. H. Coupé, H. W. M. van Laarhoven, Masaru Katoh
PLOS ONE.2018; 13(2): e0192310. CrossRef
Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review
Vaibhav Gupta, Natalie Coburn, Biniam Kidane, Kenneth R. Hess, Carolyn Compton, Jolie Ringash, Gail Darling, Alyson L. Mahar
The Journal of Thoracic and Cardiovascular Surgery.2018; 156(2): 847. CrossRef
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control
Nuria Kotecki, Sandrine Hiret, Pierre-Luc Etienne, Nicolas Penel, Emmanuelle Tresch, Eric François, Marie Pierre Galais, Meher Ben Abdelghani, Pierre Michel, Laetitia Dahan, François Ghiringelli, Laurent Bedenne, Emmanuelle Samalin, Guillaume Piessen, Jaf
Oncology.2016; 90(2): 88. CrossRef
Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib
Michael W. Kattan, Cora N. Sternberg, Faisal Mehmud, Kamal Bhatt, Lauren McCann, Robert J. Motzer
Oncology.2015; 89(4): 235. CrossRef
Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
Hyun Ae Jung, Antoine Adenis, Jeeyun Lee, Se Hoon Park, Chi Hoon Maeng, Silvia Park, Hee Kyung Ahn, Young Mog Shim, Nicolas Penel, Young-Hyuck Im
Cancer Research and Treatment.2013; 45(4): 285. CrossRef

11,586 View
88 Download
11 Crossref

Author index